{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:34:24Z","timestamp":1773804864647,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.yebeh.2022.108910","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T13:43:28Z","timestamp":1663163008000},"page":"108910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Association between anti-seizure medication and the risk of lower urinary tract infection in patients with epilepsy"],"prefix":"10.1016","volume":"135","author":[{"given":"Niklas","family":"Gremke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Printz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Ehrenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kalder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yebeh.2022.108910_b0005","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Epilepsy Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108910_b0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s10309-020-00334-8","article-title":"Wie viele Patienten mit Epilepsie gibt es in Deutschland, und wer behandelt sie?Prevalence and treatment of patients with epilepsy in Germany: Comparison of the EPIDEG studies from 1995 and 2010","volume":"33","author":"Pf\u00e4fflin","year":"2020","journal-title":"Zeitschrift f\u00fcr Epileptologie"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108910_b0020","doi-asserted-by":"crossref","first-page":"a022426","DOI":"10.1101\/cshperspect.a022426","article-title":"Seizures and epilepsy: an overview for neuroscientists","volume":"5","author":"Stafstrom","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108910_b0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108910_b0030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108910_b0035","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The pharmacological treatment of epilepsy in adults","volume":"10","author":"Perucca","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108910_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42494-021-00055-z","article-title":"The pharmacological treatment of epilepsy: recent advances and future perspectives","volume":"3","author":"Perucca","year":"2021","journal-title":"Acta Epileptol"},{"issue":"9971","key":"10.1016\/j.yebeh.2022.108910_b0045","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.yebeh.2022.108910_b0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"Loscher","year":"2011","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108910_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","article-title":"General trends in prices and prescription patterns of anticonvulsants in Germany between 2000 and 2017: analysis of national and cohort-based data","volume":"17","author":"Willems","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.yebeh.2022.108910_b0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108910_b0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(12)70105-9","article-title":"Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"11","author":"Baulac","year":"2012","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2022.108910_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2010.02602.x","article-title":"Therapeutic approaches to epileptogenesis\u2013hope on the horizon","volume":"51","author":"Pitkanen","year":"2010","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108910_b0075","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"issue":"20","key":"10.1016\/j.yebeh.2022.108910_b0080","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"issue":"9476","key":"10.1016\/j.yebeh.2022.108910_b0085","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(05)66694-9","article-title":"Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial","volume":"365","author":"Marson","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108910_b0090","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/bcp.13296","article-title":"Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies","volume":"83","author":"Zaccara","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2022.108910_b0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1528-1167.2011.03035.x","article-title":"Antiepileptic drugs and the immune system","volume":"52","author":"Beghi","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000486138","article-title":"The 2017 update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1","volume":"100","author":"Kranz","year":"2018","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108910_b0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mda.2003.7","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"49","author":"Foxman","year":"2003","journal-title":"Dis Mon"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108910_b0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108910_b0120","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.yebeh.2020.107502","article-title":"Association between antiseizure medication use and risk of urinary tract infection: A case-control study","volume":"115","author":"Heidemann","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108910_b0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: a more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J Neurosci"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108910_b0130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cns.12418","article-title":"Zonisamide: Review of recent clinical evidence for treatment of epilepsy","volume":"21","author":"Kwan","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108910_b0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2022.108910_b0140","doi-asserted-by":"crossref","first-page":"107210","DOI":"10.1016\/j.yebeh.2020.107210","article-title":"Usage of antiepileptic drugs in different diseases in Germany - A retrospective study","volume":"111","author":"Scholten","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108910_b0145","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00415-020-10379-4","article-title":"Anti-seizure medication is not associated with an increased risk to develop cancer in epilepsy patients","volume":"268","author":"Stritzelberger","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108910_b0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5414\/CP204177","article-title":"Association between contraceptive use and risk of lower urinary tract infection (LUTI): A case-control study","volume":"60","author":"Heidemann","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2022.108910_b0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2296-11-85","article-title":"Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies","volume":"11","author":"Semel","year":"2010","journal-title":"BMC Fam Pract"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108910_b0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2042098613505614","article-title":"Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain","volume":"5","author":"Toth","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"14","key":"10.1016\/j.yebeh.2022.108910_b0170","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108910_b0175","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2169\/internalmedicine.53.2085","article-title":"Clostridium difficile infection induced by pregabalin-associated agranulocytosis","volume":"53","author":"Kino","year":"2014","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0180","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.20176","article-title":"Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study","volume":"77","author":"Andersohn","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.yebeh.2022.108910_b0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.1996.tb01641.x","article-title":"Drugs in the aetiology of agranulocytosis and aplastic anaemia","volume":"60","author":"Kaufman","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.yebeh.2022.108910_b0190","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-020-61006-1","article-title":"Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide\/Concanavalin A -induced murine models of inflammation","volume":"10","author":"Abu-Rish","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2022.108910_b0195","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1213\/ANE.0b013e31825d2ad1","article-title":"The immunomodulatory effect of pregabalin on spleen cells in neuropathic mice","volume":"115","author":"Jang","year":"2012","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108910_b0200","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108910_b0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.arcmed.2003.09.016","article-title":"Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment","volume":"35","author":"Moreno","year":"2004","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1535-7511.2007.00176.x","article-title":"Oxcarbazepine and carbamazepine: expected and unexpected differences and similarities","volume":"7","author":"Abou-Khalil","year":"2007","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2022.108910_b0215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0028-3843(14)60080-3","article-title":"Epilepsy and pro-inflammatory cytokines. Immunomodulating properties of antiepileptic drugs","volume":"45","author":"Andrzejczak","year":"2011","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.yebeh.2022.108910_b0220","first-page":"799","article-title":"Effects of antiepileptic drugs on immune system","volume":"65","author":"Basta-Kaim","year":"2008","journal-title":"Przegl Lek"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108910_b0225","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.jpsychires.2013.07.026","article-title":"Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro","volume":"47","author":"Himmerich","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108910_b0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cyto.2013.12.009","article-title":"Cytokine release assays: current practices and future directions","volume":"66","author":"Finco","year":"2014","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108910_b0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10238-001-8024-1","article-title":"Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1","volume":"1","author":"Verrotti","year":"2001","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108910_b0240","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1528-1157.1995.tb01013.x","article-title":"Cytokine production in blood mononuclear cells from epileptic patients","volume":"36","author":"Pacifici","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108910_b0245","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3389\/fmicb.2019.01051","article-title":"Impact of proinflammatory cytokines on the virulence of uropathogenic Escherichia coli","volume":"10","author":"Engelsoy","year":"2019","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108910_b0250","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00467-013-2513-9","article-title":"The innate immune response during urinary tract infection and pyelonephritis","volume":"29","author":"Spencer","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108910_b0255","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CPP47617","article-title":"Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies","volume":"47","author":"Becher","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108910_b0260","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pds.3823","article-title":"No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK","volume":"24","author":"Kowall","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108910_b0265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","article-title":"Nonadherence to antiepileptic drugs in Germany: A retrospective, population-based study","volume":"87","author":"Gollwitzer","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108910_b0270","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/dom.12673","article-title":"Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study","volume":"18","author":"Rathmann","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022003596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022003596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:48:03Z","timestamp":1761504483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":54,"alternative-id":["S1525505022003596"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108910","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between anti-seizure medication and the risk of lower urinary tract infection in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108910"}}